EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?

Balen Abdulrahman, Richard J Jabbour, Nick Curzen

Interventional Cardiology: Reviews, Research, Resources · 13.06.2023 · 18

DOI: 10.15420/icr.2022.40 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Interventional Cardiology: Reviews, Research, Resources, online erschienen am 13.06.2023. Verfasst von Balen Abdulrahman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Coronary Research Group, University Hospital Southampton NHS Foundation Trust Southampton, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of AF in patients with coronary artery disease is high. The guidelines from many professional groups, including the European Society of Cardiology, American College of Cardiology/American Heart Association and Heart Rhythm Society, recommend a maximum duration of 12 months of combination single antiplatelet and anticoagulation therapy in patients who undergo percutaneous coronary intervention and who have concurrent AF, followed by anticoagulation alone beyond 1 year. However, the evidence that anticoagulation alone without antiplatelet therapy adequately reduces the well-documented attritional risk of stent thrombosis after coronary stent implantation is relatively sparse, particularly given that very late stent thrombosis (>1 year from stent implantation) is the commonest type. By contrast, the elevated risk of bleeding from combined anticoagulation and antiplatelet therapy is clinically important. The aim of this review is to assess the evidence for long-term anticoagulation alone without antiplatelet therapy 1 year post-percutaneous coronary intervention in patients with AF.

Autor:innen und Institutionen

  • Coronary Research Group, University Hospital Southampton NHS Foundation Trust Southampton, UK.
  • Faculty of Medicine, University of Southampton Southampton, UK.

Zitieren

APA

Abdulrahman, B., Jabbour, R. J., & Curzen, N. (2023). Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?. Interventional Cardiology: Reviews, Research, Resources, 18. https://doi.org/10.15420/icr.2022.40

Vancouver

Abdulrahman B, Jabbour RJ, Curzen N. Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?. Interventional Cardiology: Reviews, Research, Resources. 2023;18. doi:10.15420/icr.2022.40

BibTeX
@article{Abdulrahman2023,
  author = {Abdulrahman, Balen and Jabbour, Richard J and Curzen, Nick},
  title = {Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?},
  journal = {Interventional Cardiology: Reviews, Research, Resources},
  year = {2023},
  volume = {18},
  doi = {10.15420/icr.2022.40}
}
Kostenlos starten →